Amylyx Pharmaceuticals (AMLX) Cash & Equivalents (2021 - 2026)

Amylyx Pharmaceuticals' Cash & Equivalents history runs 6 years deep, the most recent figure standing at $229.1 million for Q1 2026.

• On a quarterly basis, Cash & Equivalents rose 283.4% year-over-year to $229.1 million in Q1 2026; TTM through Mar 2026 was $229.1 million, a 283.4% increase from a year earlier, with the FY2025 full-year figure at $226.7 million, up 192.86% from the prior year.
• Cash & Equivalents rose to $229.1 million in Q1 2026 per AMLX's latest filing, from $226.7 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $247.8 million in Q2 2023 and bottomed at $58.1 million in Q2 2025.
• The 5-year median for Cash & Equivalents is $110.4 million (2022), against an average of $130.0 million.
• Across the five-year window, Cash & Equivalents plunged 69.73% in 2024 and surged 283.4% in 2026, its largest moves.
• Year by year, Cash & Equivalents stood at $62.5 million in 2022, then surged by 172.21% to $170.2 million in 2023, then slumped by 54.53% to $77.4 million in 2024, then jumped by 192.86% to $226.7 million in 2025, then grew by 1.1% to $229.1 million in 2026.
• Per Business Quant, the three latest AMLX Cash & Equivalents figures stand at $229.1 million (Q1 2026), $226.7 million (Q4 2025), and $225.2 million (Q3 2025).